Peptide Therapy Legal Guide for Practices [2026]

Peptide therapy represents one of the most significant growth areas in cash-pay medicine, but the legal environment is complex and evolving. This guide provides medical practices with a complete reference for the regulatory, legal, and compliance considerations of offering peptide therapy in 2026.

Important: This article is for informational purposes only and does not constitute legal advice. The regulatory environment for peptides is changing rapidly. Consult qualified healthcare legal counsel before making prescribing or business decisions based on this information.

FDA Bulk Drug Substance Categories

The FDA maintains a system for categorizing bulk drug substances that determines whether they can be legally compounded. Understanding this system is foundational to peptide therapy compliance.

How the Category System Works

The FDA evaluates bulk drug substances (the raw materials used in compounding) and assigns them to categories that determine compounding eligibility. This system is part of FDA’s oversight under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Category 1: Eligible for Compounding

Category 1 substances have been evaluated by FDA and determined to be appropriate for use in compounding. When a substance holds Category 1 status:

• 503A pharmacies can compound it pursuant to a valid patient-specific prescription from a licensed prescriber
• 503B outsourcing facilities can compound it under their registered facility authority
• Prescribers can legally write prescriptions for compounded formulations
• Compounding pharmacies can maintain these substances in their formularies

Category 1 is the “green light” for peptide compounding. The FDA’s bulk drug substance lists are the authoritative source for current classifications.

Category 2: Under Evaluation (Not Eligible)

Category 2 substances are currently under FDA evaluation. During the evaluation period:

• Compounding pharmacies cannot legally compound these substances
• Prescribers cannot obtain compounded formulations through legitimate channels
• The substance remains in regulatory limbo until FDA makes a final determination
• FDA may move the substance to Category 1 (eligible) or Category 3 (rejected)

In recent years, FDA placed 19 peptides into Category 2, effectively removing them from the compounding market. This action was controversial and generated significant pushback from practitioners, patients, and compounding pharmacies.

Category 3: Rejected (Not Eligible)

Category 3 substances have been evaluated and FDA has determined they should not be used in compounding. Reasons for Category 3 placement may include:

• Safety concerns based on available evidence
• Lack of adequate characterization data
• Existence of FDA-approved alternatives that make compounding unnecessary
• Insufficient evidence of a clinical need for compounding

Category 3 is a final determination (though it can theoretically be revisited). Compounding of Category 3 substances is not permitted under either 503A or 503B pathways.

The February 2026 HHS Announcement

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides currently classified as Category 2 would be returned to Category 1, making them eligible for compounding. This announcement represented the most significant regulatory shift in the peptide therapy space in several years.

What Was Announced

The HHS announcement indicated that HHS had directed FDA to reclassify the following peptides from Category 2 back to Category 1:

• BPC-157
• Thymosin Alpha-1
• TB-500 (Thymosin Beta-4)
• CJC-1295
• Ipamorelin
• AOD-9604
• GHK-Cu
• MOTS-c
• Selank
• Semax
• KPV
• DSIP (Delta Sleep-Inducing Peptide)
• Kisspeptin-10
• GHRP-6

What Has Not Happened Yet

As of the publication date of this guide, the formal FDA rulemaking process is still underway. Key points:

1. No Federal Register publication: The formal rule change has not been published in the Federal Register, which is the official mechanism for regulatory changes
2. No updated FDA lists: The FDA’s official bulk drug substance lists have not yet been formally updated
3. Enforcement discretion: FDA’s enforcement posture during the transition period is uncertain
4. Timeline unclear: No specific date has been announced for when the formal reclassification will take effect

What This Means for Prescribers Right Now

Prescribers face a practical dilemma: there is strong political support for reclassification, but the formal legal change has not been completed. The conservative legal position is:

• Do not prescribe Category 2 peptides until the formal rule is published
• Prepare your infrastructure so you can launch quickly once the rule takes effect
• Monitor official sources including the FDA website and Federal Register
• Consult legal counsel about your specific risk tolerance and the current enforcement environment

For more detail on the expected reclassification, see our article on FDA Peptide Reclassification 2026.

State-by-State Prescribing Authority

Peptide prescribing authority is governed by both federal law (FDA classification) and state law (scope of practice, prescriptive authority). This creates a dual-layer regulatory framework.

General Prescribing Authority

In most states, the following practitioners can prescribe compounded peptides when the peptides hold Category 1 status:

• Physicians (MD/DO): Full prescriptive authority in all states
• Nurse Practitioners (NP): Prescriptive authority varies by state; some require collaborative agreements
• Physician Assistants (PA): Prescriptive authority under physician supervision in most states
• Naturopathic Physicians (ND): Limited prescriptive authority in states that license NDs

State-Specific Considerations

States vary in several important ways:

Scope of practice restrictions: Some states limit prescribing of compounded medications to physicians, while others allow mid-level providers with appropriate supervision or collaborative agreements.

Telehealth prescribing rules: States have different requirements for establishing a provider-patient relationship via telehealth. Some require an initial in-person visit; others permit fully virtual relationships. The Federation of State Medical Boards (FSMB) maintains resources on state telehealth policies.

Compounding pharmacy regulations: State boards of pharmacy may impose additional requirements on compounding pharmacies operating within their borders, which can affect medication availability.

Off-label prescribing: While off-label prescribing is generally legal for licensed physicians, some states have specific disclosure or documentation requirements.

Verifying Your State’s Requirements

Before launching a peptide therapy program, verify requirements with:

1. Your state medical board: FSMB State Medical Board Directory
2. Your state board of pharmacy: For compounding-specific regulations
3. Your state nursing board: If NPs will be prescribing in your practice
4. Healthcare legal counsel: For interpretation of ambiguous regulations

Multi-State Practice Considerations

If your practice serves patients across state lines (common with telehealth), you must comply with the regulations of:

• The state where you are licensed and physically located
• The state where the patient is physically located at the time of the encounter
• Any interstate compact requirements (if applicable)

The Interstate Medical Licensure Compact (IMLC) facilitates multi-state licensing but does not override individual state prescribing regulations.

DEA Considerations

While most therapeutic peptides are not currently scheduled controlled substances, DEA considerations remain relevant for peptide therapy practices.

Current Scheduling Status

As of 2026, no commonly prescribed therapeutic peptides (BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, etc.) are listed on the DEA’s Controlled Substances Schedules. This means:

• No DEA registration is specifically required for peptide prescribing
• No Schedule II-V prescribing requirements apply
• No DEA reporting or monitoring requirements for peptide prescriptions
• No prescription monitoring program (PMP) obligations for peptides

Why DEA Registration Still Matters

Prescribers should maintain current DEA registration because:

• Many practices prescribe controlled substances alongside peptides (e.g., testosterone in TRT programs)
• DEA registration is part of general prescriptive authority verification
• Some pharmacy systems require active DEA numbers for electronic prescribing
• If any peptide were to be scheduled in the future, you would need current registration

Growth Hormone Releasing Peptides: A Special Case

Growth hormone releasing peptides (GHRPs) and growth hormone releasing hormone (GHRH) analogs deserve special attention:

• Growth hormone itself (somatotropin) is not a controlled substance but is subject to specific federal restrictions under 21 USC 333(e), which prohibits distribution for non-medical purposes
• GHRP-6, CJC-1295, Ipamorelin: Not scheduled, but prescribers should document legitimate medical purposes
• Anti-doping considerations: Many peptides are banned by WADA and sports organizations; counsel patients who are competitive athletes

Potential Future Scheduling

Monitor DEA announcements for any scheduling actions involving peptides. If a commonly prescribed peptide were added to a controlled substance schedule, practices would need to immediately implement controlled substance protocols including secure storage, DEA Form 222 ordering, and prescription monitoring program reporting.

Informed Consent Requirements

Informed consent is both an ethical obligation and a legal requirement for peptide therapy. Because most peptide applications are off-label and the medications are compounded (not FDA-approved for the specific indication), informed consent takes on particular importance.

Essential Elements of Peptide Therapy Informed Consent

Your informed consent documentation should address:

1. Nature of the treatment

• Specific peptide(s) being prescribed
• Route of administration (subcutaneous injection, oral, nasal, topical)
• Proposed dosing protocol and duration
• Expected timeline for results

2. FDA and regulatory status

• The peptide is compounded, not an FDA-approved finished drug product
• Most peptide applications are off-label
• The regulatory classification may change
• The medication has not undergone the same clinical trial process as FDA-approved drugs

3. Benefits and risks

• Expected therapeutic benefits based on available evidence
• Known side effects and adverse reactions
• Unknown risks due to limited long-term data
• Injection site reactions (for subcutaneous administration)

4. Alternatives

• FDA-approved alternatives, if any exist
• Non-pharmacological alternatives
• Option to decline treatment

5. Compounding-specific disclosures

• The medication is prepared by a compounding pharmacy
• The name of the compounding pharmacy
• Quality controls in place (without guaranteeing equivalence to FDA-approved products)
• Storage and handling requirements

6. Patient responsibilities

• Proper self-injection technique (if applicable)
• Storage requirements (many peptides require refrigeration)
• Reporting adverse effects promptly
• Following the prescribed dosing protocol
• Attending follow-up appointments

Documentation Best Practices

• Obtain written, signed informed consent before initiating therapy
• Document the consent discussion in the clinical record (date, topics covered, patient questions)
• Update consent forms when regulatory conditions change
• Re-consent patients when adding new peptides or significantly changing protocols
• Maintain copies of all signed consent forms in the patient record

Documentation Best Practices

Thorough documentation protects prescribers, practices, and patients. For peptide therapy, documentation standards should exceed the minimum because of the off-label, compounded nature of the medications.

Clinical Documentation for Each Patient

Initial evaluation:

• Chief complaint and treatment goals
• Relevant medical history and review of systems
• Current medications (checking for interactions)
• Relevant laboratory results
• Physical examination findings (if indicated)
• Clinical assessment and plan
• Rationale for peptide therapy selection

Prescription documentation:

• Specific peptide, dose, concentration, volume, and route
• Frequency and duration
• Compounding pharmacy selected and rationale
• Any special instructions

Follow-up documentation:

• Patient-reported outcomes (symptom changes, side effects)
• Objective measures when applicable (labs, weight, body composition)
• Treatment modifications and rationale
• Ongoing informed consent (especially if adding peptides or changing protocols)

Program-Level Documentation

Beyond individual patient records, maintain:

• Standard operating procedures (SOPs) for your peptide therapy program
• Prescribing protocols that outline your clinical approach to each peptide
• Pharmacy partner documentation including Business Associate Agreements, quality certifications, and contact information
• Staff training records for clinical and administrative team members
• Adverse event logs tracking any reported adverse reactions
• Regulatory update file documenting how you monitor and respond to regulatory changes

EHR Considerations

If your EHR system does not have built-in support for compounded medication workflows, consider:

• Custom templates for peptide therapy visits
• Structured fields for informed consent documentation
• Integration with compounding pharmacy ordering systems
• Automated follow-up scheduling
• Lab result tracking linked to peptide protocols

Platforms like Karpa Health provide purpose-built clinical workflows for peptide therapy that handle documentation, pharmacy integration, and patient management.

Malpractice Considerations

Peptide therapy introduces specific malpractice risk factors that practices should address proactively.

Common Malpractice Risk Areas

Off-label prescribing liability: While off-label prescribing is legal, prescribers must demonstrate clinical rationale. Document your reasoning, cite supporting literature when available, and ensure informed consent addresses the off-label nature.

Standard of care questions: Because peptide therapy is relatively new and protocols are not universally standardized, the “standard of care” can be difficult to define. Follow published protocols from reputable sources, document your clinical decision-making, and stay current with evolving best practices.

Compounding pharmacy quality: If a patient experiences harm from a contaminated or incorrectly formulated compounded peptide, the prescribing practice may face liability questions. Mitigate this by using only reputable pharmacies with documented quality programs.

Telehealth-specific risks: If prescribing via telehealth, ensure your evaluation meets the standard of care for your state. Document that the telehealth encounter was clinically appropriate for the services provided.

Scope of practice issues: Ensure all prescribers in your practice are prescribing within their licensed scope. This is particularly important for mid-level providers.

Insurance Coverage Steps

1. Contact your carrier before launching: Notify your malpractice insurance provider of your plans to offer peptide therapy
2. Confirm coverage: Verify that compounded medication prescribing, off-label prescribing, and telehealth (if applicable) are covered
3. Ask about exclusions: Some policies exclude “experimental” treatments; clarify whether peptide therapy falls into any exclusion
4. Obtain riders if needed: If your base policy does not cover peptide therapy, ask about available riders
5. Document the confirmation: Keep written confirmation of coverage in your files

Risk Mitigation Strategies

• Maintain detailed clinical documentation for every patient
• Follow established protocols and document deviations with clinical rationale
• Use only reputable compounding pharmacies with quality certifications
• Obtain thorough informed consent
• Stay within your scope of practice and training
• Participate in continuing education on peptide therapy
• Maintain open communication with patients about expectations and limitations

Compliance Checklist for Peptide Therapy Programs

Use this checklist when setting up or auditing your peptide therapy program:

Federal Regulatory Compliance

• Verify FDA category status for each peptide you plan to prescribe
• Confirm compounding pharmacy operates under valid 503A or 503B authority
• Verify no DEA scheduling applies to your peptide formulary
• Review FTC advertising requirements for claims about peptide therapy
• Ensure HIPAA compliance for patient data handling (see HIPAA guidance for cash-pay programs)

State Regulatory Compliance

• Verify prescriptive authority under your state medical board
• Confirm state board of pharmacy compounding regulations
• Review state telehealth regulations (if offering virtual consultations)
• Verify mid-level provider supervision requirements (if applicable)
• Check state-specific informed consent requirements

Clinical Infrastructure

• Develop clinical protocols for each peptide offered
• Create informed consent documents
• Establish patient screening criteria and contraindication lists
• Set up lab ordering and result monitoring workflows
• Implement adverse event reporting procedures

Business and Legal

• Confirm malpractice insurance coverage
• Execute Business Associate Agreements with pharmacy partners
• Review marketing materials for regulatory compliance
• Establish financial policies and patient payment agreements
• Document all vendor relationships and agreements

Ongoing Monitoring

• Subscribe to FDA compounding updates
• Monitor HHS announcements for policy changes
• Review state medical board communications quarterly
• Update protocols and consent forms when regulations change
• Conduct annual compliance audits

Resources for Staying Current

The peptide therapy regulatory environment changes frequently. Maintain awareness through these authoritative sources:

Federal Resources

• FDA Bulk Drug Substances Used in Compounding
• FDA Human Drug Compounding
• HHS News and Communications
• Federal Register: FDA Rules
• DEA Controlled Substances Schedules

State Resources

• FSMB State Medical Board Directory
• NABP State Board of Pharmacy Directory
• FSMB Telemedicine Policies

Professional Organizations

• Alliance for Pharmacy Compounding
• American Academy of Anti-Aging Medicine (A4M)
• International Peptide Society

How Karpa Health Supports Compliant Peptide Programs

Karpa Health provides the operational platform for practices to offer peptide therapy programs with built-in compliance infrastructure:

• Structured patient intake with customizable screening questions and consent workflows
• AI-assisted clinical review that flags contraindications and prepares clinical summaries for physician approval
• Integrated prescribing to compliant compounding pharmacies with electronic prescription routing
• Documentation automation that maintains detailed clinical records
• Pharmacy partner vetting: Karpa integrates only with pharmacies that meet quality and compliance standards

The platform handles peptide therapy, GLP-1 weight loss, TRT, and HRT from a single system, allowing practices to build diversified programs efficiently.

Book a demo to see how Karpa’s compliance infrastructure works for your practice. For answers to common questions, visit our FAQ.

This article is for informational purposes only and does not constitute legal advice. Peptide therapy regulations are evolving rapidly in 2026. Consult qualified healthcare legal counsel for advice specific to your practice, state, and clinical situation. Last reviewed: May 2026.